We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
AdaptHealth (AHCO) Surges 10.7%: Is This an Indication of Further Gains?
Read MoreHide Full Article
AdaptHealth Corp. (AHCO - Free Report) shares rallied 10.7% in the last trading session to close at $11.48. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 0.8% gain over the past four weeks.
The sharp rise in AHCO shares can be attributed to a strong vote of confidence from its leadership, as Chief Executive Officer Richard Cashin made a substantial insider purchase. Over March 19 and 20, Cashin acquired nearly 447,827 shares at an average price of $9.91, representing a total investment of about $4.44 million and increasing his total holdings to 16.3 million shares. This significant buy signals management’s confidence in the company’s future prospects, boosting investor sentiment and reinforcing the belief that the stock may be undervalued at current levels.
This company is expected to post break-even quarterly earnings per share in its upcoming report, which represents a year-over-year change of -100%. Revenues are expected to be $798.14 million, up 2.6% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For AdaptHealth, the consensus EPS estimate for the quarter has been revised 350% lower over the last 30 days to the current level. And a negative trend in earnings estimate revisions doesn't usually translate into price appreciation. So, make sure to keep an eye on AHCO going forward to see if this recent jump can turn into more strength down the road.
AdaptHealth belongs to the Zacks Medical - Products industry. Another stock from the same industry, AtriCure (ATRC - Free Report) , closed the last trading session 0.6% lower at $29.61. Over the past month, ATRC has returned -6.3%.
AtriCure's consensus EPS estimate for the upcoming report has remained unchanged over the past month at -$0.07. Compared to the company's year-ago EPS, this represents a change of +50%. AtriCure currently boasts a Zacks Rank of #3 (Hold).
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
AdaptHealth (AHCO) Surges 10.7%: Is This an Indication of Further Gains?
AdaptHealth Corp. (AHCO - Free Report) shares rallied 10.7% in the last trading session to close at $11.48. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 0.8% gain over the past four weeks.
The sharp rise in AHCO shares can be attributed to a strong vote of confidence from its leadership, as Chief Executive Officer Richard Cashin made a substantial insider purchase. Over March 19 and 20, Cashin acquired nearly 447,827 shares at an average price of $9.91, representing a total investment of about $4.44 million and increasing his total holdings to 16.3 million shares. This significant buy signals management’s confidence in the company’s future prospects, boosting investor sentiment and reinforcing the belief that the stock may be undervalued at current levels.
This company is expected to post break-even quarterly earnings per share in its upcoming report, which represents a year-over-year change of -100%. Revenues are expected to be $798.14 million, up 2.6% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For AdaptHealth, the consensus EPS estimate for the quarter has been revised 350% lower over the last 30 days to the current level. And a negative trend in earnings estimate revisions doesn't usually translate into price appreciation. So, make sure to keep an eye on AHCO going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
AdaptHealth belongs to the Zacks Medical - Products industry. Another stock from the same industry, AtriCure (ATRC - Free Report) , closed the last trading session 0.6% lower at $29.61. Over the past month, ATRC has returned -6.3%.
AtriCure's consensus EPS estimate for the upcoming report has remained unchanged over the past month at -$0.07. Compared to the company's year-ago EPS, this represents a change of +50%. AtriCure currently boasts a Zacks Rank of #3 (Hold).